High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Jesús Loarce-Martos,Antía García-Fernández,Fernando López-Gutiérrez,Verónica García-García,Laura Calvo-Sanz,Iván Del Bosque-Granero,M Andreína Terán-Tinedo,Alina Boteanu,J. Bachiller-Corral,Mónica Vázquez-Díaz +9 more
Reads0
Chats0
TLDR
Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD, with a high rate of severe disease requiring hospitalization and a high mortality rate.Abstract:
The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020-26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28-76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjogren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.read more
Citations
More filters
Journal ArticleDOI
Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19
Manfred Nairz,Sabina Sahanic,Alex Pizzini,A Böhm,Piotr Tymoszuk,Anna-Maria Mitterstiller,Laura von Raffay,Philipp Grubwieser,Rosa Bellmann-Weiler,Sabine Koppelstätter,Andrea Schroll,David Haschka,Martina Zimmermann,Silvia Blunder,Kristina Trattnig,Helene Naschberger,Werner Klotz,Igor Theurl,Verena Petzer,Clemens M Gehrer,John E. Mindur,Anna Luger,Christoph Schwabl,Gerlig Widmann,Günter Weiss,Judith Löffler-Ragg,Ivan Tancevski,Thomas Sonnweber +27 more
TL;DR: The CovILD study as mentioned in this paper evaluated 145 patients at 3 follow-up visits scheduled for 60, 100, and 180 days after initial confirmed diagnosis based on typical symptoms and a positive reverse transcription-polymerase chain reaction for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Journal ArticleDOI
COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.
Berkan Armagan,Mehmet Akif Eksin,Serdar Can Güven,Bahar Özdemir,Pınar Akyüz Dağlı,Orhan Küçükşahin,Ahmet Omma,Abdulsamet Erden +7 more
TL;DR: In this paper , the authors conducted a systematic literature review using different spelling combinations of COVID-19 and polyangiitis (GPA) in the PUBMED database.
Journal ArticleDOI
Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe : Ein Positionspapier der Osterreichischen Gesellschaft fur Allergologie und Immunologie (OGAI) und des Arzteverbands Deutscher Allergologen (AeDA)
Eva Untersmayr,E. Förster-Waldl,M Bonelli,Kaan Boztug,Patrick Manfred Brunner,Thomas Eiwegger,Kathrin Eller,Lisa Göschl,Katharina Grabmeier-Pfistershammer,Wolfram Hötzenecker,Galateja Jordakieva,Alexander R. Moschen,Birgit Pfaller,Winfried F. Pickl,Walter Reinisch,Ursula Wiedermann,Ludger Klimek,Karl-Christian Bergmann,Randolf Brehler,Natalija Novak,HF Merk,Uta Rabe,Wolfgang W. Schlenter,Johannes Ring,W. Wehrmann,Norbert Mülleneisen,Holger Wrede,Thomas Fuchs,Erika Jensen-Jarolim +28 more
Journal ArticleDOI
Plasma exchange with COVID-19 convalescent plasma in a patient with severe ANCA-associated vasculitis and COVID-19 pneumonia after rituximab therapy
Matthias Kochanek,Jorge Garcia Borrega,Laura Beckmann,Julia Neuhann,Birgit Gathof,Veronica Di Cristanziano,Henning Hagmann,Garcia Borrega +7 more
References
More filters
Journal ArticleDOI
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
TL;DR: It is found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds ofospitalisation in patients with rheumatic disease.
Journal ArticleDOI
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Sara Monti,Silvia Balduzzi,Paolo Delvino,E. Bellis,Verdiana Serena Quadrelli,Carlomaurizio Montecucco +5 more
TL;DR: The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs followed up at the biological outpatient clinic in Pavia, Lombardy.
Journal ArticleDOI
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Rebecca H. Haberman,Jordan E. Axelrad,Alan Chen,Rochelle Castillo,Di Yan,Peter M. Izmirly,Andrea L. Neimann,Samrachana Adhikari,David Hudesman,Jose U. Scher +9 more
TL;DR: Patients in New York City with known immune-mediated inflammatory disease in whom Covid-19 developed while they were receiving treatment with the drug are described.
Journal ArticleDOI
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
Kristin M. D’Silva,Naomi Serling-Boyd,Rachel Wallwork,Tiffany Y.T. Hsu,Xiaoqing Fu,Ellen M. Gravallese,Hyon K. Choi,Jeffrey A. Sparks,Zachary S. Wallace +8 more
TL;DR: Patients with rheumatic disease and COVID-19 infection were more likely to require mechanical ventilation but had similar clinical features and hospitalisation rates as those without rhematic disease.
Journal ArticleDOI
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Xabier Michelena,Xabier Michelena,Helena Borrell,Mireia López-Corbeto,María López-Lasanta,Estefanía Moreno,María Pascual-Pastor,Alba Erra,Mayte Serrat,Esther Espartal,Susana Antón,Gustavo Adolfo Añez,Raquel Caparrós-Ruiz,Andrea Pluma,Ernesto Trallero-Araguás,Mireia Barceló-Bru,Miriam Almirall,Juan José De Agustín,Jordi Lladós,Antonio Julià,Sara Marsal +20 more
TL;DR: Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population.
Related Papers (5)
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
Factors associated with COVID-19-related death using OpenSAFELY.
Elizabeth A. Williamson,Alex J Walker,Krishnan Bhaskaran,Seb Bacon,Chris Bates,Caroline E Morton,Helen J Curtis,Amir Mehrkar,David M. Evans,Peter Inglesby,Jonathan Cockburn,Helen Mcdonald,Brian MacKenna,Laurie A. Tomlinson,Ian J. Douglas,Christopher T Rentsch,Rohini Mathur,Angel Y S Wong,Richard Grieve,David G. Harrison,Harriet Forbes,Anna Schultze,Richard Croker,John Parry,Frank Hester,Sam Harper,Rafael Perera,Stephen J. W. Evans,Liam Smeeth,Ben Goldacre +29 more